Treatment of acute ischemic stroke

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Acute ischemic stroke remains difficult to treat despite the advent of new therapies. The only approved medication to reverse its effects is recombinant tissue plasminogen activator administered intravenously within 3 hours of onset of stroke symptoms - an opportunity that does not often present itself. The principal draw-back to thrombolytic therapy for acute ischemic stroke is a 3% to 6% occurrence of symptomatic cerebral hemorrhage. Although intra-arterial recombinant prourokinase also appears to be effective, it has not been approved by the Food and Drug Administration. Aspirin administered within 48 hours of stroke onset can Prevent a few recurrent strokes and deaths. The efficacy of heparin and heparinoids in acute ischemic stroke has not been shown. Despite their theoretical attractiveness and laboratory results, neuroprotective agents have not proven effective in clinical trials. In view of current limitations on the ability to treat and reverse the effects of acute ischemic stroke, improved preventive measures in patients at risk for stroke are urgently needed.

Original languageEnglish (US)
Pages (from-to)10-17
Number of pages8
JournalJournal of Stroke and Cerebrovascular Diseases
Volume10
Issue number2 SUPPL. 1
DOIs
StatePublished - 2001

Fingerprint

Stroke
saruplase
Therapeutics
Heparinoids
Thrombolytic Therapy
Cerebral Hemorrhage
Neuroprotective Agents
Tissue Plasminogen Activator
United States Food and Drug Administration
Aspirin
Heparin
Clinical Trials

Keywords

  • Acute ischemic stroke
  • Anticoagulant therapy
  • Antiplatelet therapy
  • Neuroprotection
  • Thrombolytic agents

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery
  • Health Professions(all)

Cite this

Treatment of acute ischemic stroke. / Alberts, Mark J.

In: Journal of Stroke and Cerebrovascular Diseases, Vol. 10, No. 2 SUPPL. 1, 2001, p. 10-17.

Research output: Contribution to journalArticle

@article{f5e9bb8041784d50ba550054234f0b6e,
title = "Treatment of acute ischemic stroke",
abstract = "Acute ischemic stroke remains difficult to treat despite the advent of new therapies. The only approved medication to reverse its effects is recombinant tissue plasminogen activator administered intravenously within 3 hours of onset of stroke symptoms - an opportunity that does not often present itself. The principal draw-back to thrombolytic therapy for acute ischemic stroke is a 3{\%} to 6{\%} occurrence of symptomatic cerebral hemorrhage. Although intra-arterial recombinant prourokinase also appears to be effective, it has not been approved by the Food and Drug Administration. Aspirin administered within 48 hours of stroke onset can Prevent a few recurrent strokes and deaths. The efficacy of heparin and heparinoids in acute ischemic stroke has not been shown. Despite their theoretical attractiveness and laboratory results, neuroprotective agents have not proven effective in clinical trials. In view of current limitations on the ability to treat and reverse the effects of acute ischemic stroke, improved preventive measures in patients at risk for stroke are urgently needed.",
keywords = "Acute ischemic stroke, Anticoagulant therapy, Antiplatelet therapy, Neuroprotection, Thrombolytic agents",
author = "Alberts, {Mark J.}",
year = "2001",
doi = "10.1053/jscd.2001.24778",
language = "English (US)",
volume = "10",
pages = "10--17",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 1",

}

TY - JOUR

T1 - Treatment of acute ischemic stroke

AU - Alberts, Mark J.

PY - 2001

Y1 - 2001

N2 - Acute ischemic stroke remains difficult to treat despite the advent of new therapies. The only approved medication to reverse its effects is recombinant tissue plasminogen activator administered intravenously within 3 hours of onset of stroke symptoms - an opportunity that does not often present itself. The principal draw-back to thrombolytic therapy for acute ischemic stroke is a 3% to 6% occurrence of symptomatic cerebral hemorrhage. Although intra-arterial recombinant prourokinase also appears to be effective, it has not been approved by the Food and Drug Administration. Aspirin administered within 48 hours of stroke onset can Prevent a few recurrent strokes and deaths. The efficacy of heparin and heparinoids in acute ischemic stroke has not been shown. Despite their theoretical attractiveness and laboratory results, neuroprotective agents have not proven effective in clinical trials. In view of current limitations on the ability to treat and reverse the effects of acute ischemic stroke, improved preventive measures in patients at risk for stroke are urgently needed.

AB - Acute ischemic stroke remains difficult to treat despite the advent of new therapies. The only approved medication to reverse its effects is recombinant tissue plasminogen activator administered intravenously within 3 hours of onset of stroke symptoms - an opportunity that does not often present itself. The principal draw-back to thrombolytic therapy for acute ischemic stroke is a 3% to 6% occurrence of symptomatic cerebral hemorrhage. Although intra-arterial recombinant prourokinase also appears to be effective, it has not been approved by the Food and Drug Administration. Aspirin administered within 48 hours of stroke onset can Prevent a few recurrent strokes and deaths. The efficacy of heparin and heparinoids in acute ischemic stroke has not been shown. Despite their theoretical attractiveness and laboratory results, neuroprotective agents have not proven effective in clinical trials. In view of current limitations on the ability to treat and reverse the effects of acute ischemic stroke, improved preventive measures in patients at risk for stroke are urgently needed.

KW - Acute ischemic stroke

KW - Anticoagulant therapy

KW - Antiplatelet therapy

KW - Neuroprotection

KW - Thrombolytic agents

UR - http://www.scopus.com/inward/record.url?scp=0034951978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034951978&partnerID=8YFLogxK

U2 - 10.1053/jscd.2001.24778

DO - 10.1053/jscd.2001.24778

M3 - Article

C2 - 17903844

AN - SCOPUS:0034951978

VL - 10

SP - 10

EP - 17

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 2 SUPPL. 1

ER -